Shaun Tolan

Clatterbridge Cancer Centre NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

19h-index4.1kcitations39works33.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(22), Prostate Cancer Diagnosis and Treatment(18), Advanced Radiotherapy Techniques(13), Breast Cancer Treatment Studies(5), Radiopharmaceutical Chemistry and Applications(5)

Publications37 total

Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)
International Journal of Radiation Oncology*Biology*Physics·2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial
The Lancet Oncology·2025· 20 citedOpen Access
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
New England Journal of Medicine·2024· 174 citedOpen Access
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial
European Urology·2024· 47 citedOpen Access
3395: Acute toxicity from PACE-C comparing Stereotactic Body Radiotherapy (SBRT) with moderate hypofractionation (MHRT)
Radiotherapy and Oncology·2024· 3 cited
1244: A retrospective analysis of patients treated with SABR for oligometastatic prostate cancer.
Radiotherapy and Oncology·2024
Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicity
Clinical and Translational Radiation Oncology·2024· 7 citedOpen Access
5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer
International Journal of Radiation Oncology*Biology*Physics·2023· 49 cited
Validating a Simple Urethra Surrogate Model to Facilitate Dosimetric Analysis to Predict Genitourinary Toxicity
International Journal of Radiation Oncology*Biology*Physics·2023Open Access
PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.
Journal of Clinical Oncology·2023· 31 cited
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
The Lancet Oncology·2022· 281 citedOpen Access
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
JNCI Cancer Spectrum·2022· 24 citedOpen Access
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
The Breast Journal·2022· 7 citedOpen Access
Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy
Clinical Oncology·2022· 6 cited
OC-0289 Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy)
Radiotherapy and Oncology·2021· 4 cited
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
Annals of Oncology·2020· 5 citedOpen Access
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
The Lancet Oncology·2019· 519 citedOpen Access
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
Annals of Oncology·2019· 389 citedOpen Access
Patient Reported Acute Toxicity in PACE-B, an International Phase III Randomised Controlled Trial Comparing Stereotactic Body Radiotherapy to Conventionally Fractionated or Moderately Hypofractionated Radiotherapy (CFMHRT) for Localised Prostate Cancer
International Journal of Radiation Oncology*Biology*Physics·2019· 1 cited
Real-world data regarding the efficacy of neoadjuvant carboplatin-paclitaxel followed by dose-dense adriamycin-cyclophosphamide for triple-negative early breast cancer.
Journal of Clinical Oncology·2019
page 1 of 2Next →

Frequent Co-authors

Alison Tree(14), Olivia Naismith(12), John Staffurth(11), Peter Ostler(11), Stephanie Brown(11), Daniel Ford(10), Stephanie Burnett(10), Clare Griffin(10), Emma Hall(10), Nicholas van As(10), Douglas Brand(9), H. van der Voet(9), Nicholas D. James(8), Matthew R. Sydes(8), Malcolm D. Mason(8), A.W.S. Ritchie(8), Robert J. Jones(8), John Wagstaff(8), William Chu(8), Suneil Jain(8)